Cell and Gene Therapy Logistics: Managing Cryogenic and Time-Critical Shipments

Hook A dry shipper that tips on its side loses vapor pressure fast, and once a cryogenic shipment drifts out of range there is no second batch in a freezer to replace it. Cell and gene therapy logistics does not have the safety net that conventional cold chain does. Most shipments are irreplaceable, patient-specific, and built around a manufacturing slot that will not wait for a delayed flight or a customs hold. Getting a living cell therapy from apheresis to infusion, or a viral vector from a contract development and manufacturing organization (CDMO) to clinic, means treating every leg of the journey as time-critical from the moment it leaves the collection site.

Autologous vs. Allogeneic: Why the Distinction Drives the Entire Logistics Model

Cell and gene therapy (CGT) logistics operates at temperatures far outside standard cold chain logistics parameters, and on a schedule where no production buffer exists. But the single factor that most determines the logistics model is whether a therapy is autologous or allogeneic.

Factor	Autologous	Allogeneic
Cell source	Patient’s own cells	Donor-derived cells
Manufacturing	Patient-specific, one batch per patient	Scalable, inventory-held
Logistics model	Closed vein-to-vein loop	Standard distribution with inventory buffer
Delay consequence	Missed window may force full collection and manufacturing restart	Can buffer against delay with existing inventory
Replaceability	Not replaceable	Can be reordered from inventory

A typical autologous chimeric antigen receptor T-cell (CAR-T) journey illustrates the stakes. Cells are collected via apheresis on day zero, shipped under cryogenic conditions to a manufacturing site over the following one to two days, then spend two to four weeks in manufacturing that cannot be accelerated or combined with another patient’s batch. Every leg has to land inside a validated window. There is no expedited reorder if a shipment misses its connection, because there is nothing left to reorder from.

Temperature Regimes in Cell and Gene Therapy Logistics

Depending on the product and its stability profile, a CGT shipment moves under one of three distinct temperature regimes, each requiring a different cold chain approach:

Temperature Regime	Range	Typical Use Case
Cryogenic	-150°C to -196°C	Cryopreserved cell therapies and most viral vector products
Ultra-Cold	Approximately -80°C	Products with more stability margin than fully cryogenic material
Refrigerated	2°C to 8°C	Fresh, non-cryopreserved cell products with short viable windows

Standard dry ice reaches approximately -78.5°C (source), which does not meet the cryogenic specification for most CGT products and is not an appropriate substitute for liquid nitrogen-based shipping. Getting the temperature regime wrong during a handoff is one of the fastest ways to compromise a product that cannot be remade.

Chain of Identity and Chain of Custody for Patient-Specific Material

For autologous products, two documentation threads run alongside the physical shipment. Chain of identity confirms that the material moving through the supply chain belongs to one specific, correctly identified patient at every step from collection through infusion. Chain of custody documents who physically held that material and under what conditions at each handoff.

A gap in either record is not just a GDP compliance issue. Infusing the wrong patient’s cells is not a recoverable error, which is why both chains must be complete, continuous, and verifiable before product is ever administered.

Cryogenic Shipping and Storage Requirements

Meeting a cryogenic temperature specification on paper is one thing. Holding it across multiple handoffs, airports, and time zones over several days is what actually determines whether a shipment survives the trip.

Dry Vapor Shippers and Dewars

Dry vapor liquid nitrogen (LN2) shippers, commonly called dewars, are the industry standard for cryogenic shipping because they hold temperature without the spill risk of liquid LN2. A properly charged dewar typically maintains a validated hold time of 7 to 10 days (source), but that window depends heavily on the shipper remaining upright throughout transit. Tip it on its side and vapor loss accelerates, cutting remaining hold time sharply, potentially below what the remaining journey requires.

Continuous Data Logging and Monitoring

Cryogenic storage and transit both rely on built-in data loggers that record temperature and often orientation and shock for the full duration of a shipment. That continuous record is what lets a receiving site or manufacturer confirm the product stayed within range before it is ever opened. A shipment that cannot produce a complete temperature record on arrival creates a disposition question no sponsor wants at the point of infusion.

Regulatory Context for Cell and Gene Therapy Logistics

CGT logistics operates inside a distinct regulatory category, separate from standard drug distribution, and compliance has to account for both sides of it. In the EU, gene therapy, somatic cell therapy, and tissue-engineered products are classified as advanced therapy medicinal products (ATMPs) under Regulation (EC) No 1394/2007, with authorization and manufacturing requirements separate from conventional medicines. In the U.S., the FDA regulates cell and gene therapies as biologics under Section 351 of the Public Health Service Act, and sponsors can pursue Regenerative Medicine Advanced Therapy (RMAT) designation, created by the 21st Century Cures Act (2016), for an expedited development pathway.

Logistics providers handling these products need to understand both frameworks and maintain documentation that holds up under inspection in either jurisdiction.

Risk Factors That Threaten a Cell and Gene Therapy Shipment

A handful of failure points account for most CGT logistics problems, and each is sharper in consequence than the equivalent failure in a conventional pharma shipment. Customs delays are particularly dangerous: a cryogenic shipment held at the border keeps burning through dewar hold time regardless of how quickly a documentation issue gets resolved. Rough handling, extended ground transit, or an aging dewar with a degraded vacuum seal can each cut hold time below what the remaining transit requires. A late pickup or delayed connection does not just push a delivery date: it can miss the exact manufacturing slot a CDMO has reserved for that patient.

These patterns are covered in depth at clinical trial logistics challenges, but CGT shipments leave far less room for any of those failures to stay contained.

Explore Eagle’s pharmaceutical and life science logistics solutions to see how coordinated cell and gene therapy logistics protects your next time-critical shipment.

Explore Our Services

How Eagle Handles Cell and Gene Therapy Logistics

Eagle Life Science supports cell and gene therapy logistics through coordination, not through owning cryogenic freezers. Eagle’s facility near Logan Airport shortens the ground transit window that eats into a dry shipper’s validated hold time on both legs of a vein-to-vein shipment. For the specialized cryogenic handling itself, Eagle works through its domestic GDP-certified partner network and international air and ocean freight capabilities, matching each shipment to the right cryogenic-capable provider for that specific lane rather than forcing every study into a single fixed setup.

Fleet visibility through Samsara keeps sponsors and CDMOs informed of shipment status at every leg. A U.S. Customs Bonded facility with an FDA-certified exam station prevents the documentation holds a cryogenic shipment cannot absorb. Eagle’s GxP-compliant warehousing and GDP-certified quality management system cover any staging or temperature-controlled storage needs that arise before or after a cryogenic leg. Eagle currently supports 100+ active life science clients across pharmaceutical, biotech, and clinical research organizations.